李新, 韩峰, 张小涛, 张真, 韩淑红. NP方案联合同步调强放疗治疗局部晚期非小细胞肺癌的临床观察[J]. 中国肿瘤临床, 2012, 39(23): 1964-1967. DOI: 10.3969/j.issn.1000-8179.2012.23.024
引用本文: 李新, 韩峰, 张小涛, 张真, 韩淑红. NP方案联合同步调强放疗治疗局部晚期非小细胞肺癌的临床观察[J]. 中国肿瘤临床, 2012, 39(23): 1964-1967. DOI: 10.3969/j.issn.1000-8179.2012.23.024
shu
Xin LI, Feng HAN, Xiaotao ZHANG, Zhen ZHANG, Shuhong HAN. Clinical Observation of NP Chemotherapy Combined with Intensity-modulated Radiotherapy in Treating stage-ⅢNon-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(23): 1964-1967. DOI: 10.3969/j.issn.1000-8179.2012.23.024
Citation: Xin LI, Feng HAN, Xiaotao ZHANG, Zhen ZHANG, Shuhong HAN. Clinical Observation of NP Chemotherapy Combined with Intensity-modulated Radiotherapy in Treating stage-ⅢNon-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(23): 1964-1967. DOI: 10.3969/j.issn.1000-8179.2012.23.024
shu

NP方案联合同步调强放疗治疗局部晚期非小细胞肺癌的临床观察

Clinical Observation of NP Chemotherapy Combined with Intensity-modulated Radiotherapy in Treating stage-ⅢNon-small Cell Lung Cancer

    摘要
  • 摘要:
      目的  探讨NP方案联合调强放疗治疗局部晚期非小细胞肺癌的临床疗效和不良作用。
      方法  72例Ⅲ期非小细胞肺癌患者随机分为2组, 治疗组36例给予NP方案化疗, 长春瑞滨25 mg/m2, d1, d8;DDP 75mg/m2, d1, 21d为1个周期, 至少2个周期。化疗同时给予调强常规分割放疗, 照射剂量为60~64Gy。对照组36例仅给予相同方法的放疗。治疗完成4周后评价疗效及不良反应。
      结果  治疗组与对照组的有效率(RR)分别为72.2%和41.7%(P < 0.05), 中位疾病进展时间(TTP)分别为7.2个月和5.8个月。治疗组与对照组的主要不良反应: Ⅲ~Ⅳ度骨髓抑制分别为20例和5例, Ⅲ~Ⅳ度胃肠道反应为6例和0例, Ⅲ~Ⅳ度放射性食管炎和放射性肺炎为4例和3例、5例和2例。
      结论  NP方案化疗联合同步调强放疗对局部晚期非小细胞肺癌有较好的近期疗效, 不良反应可以耐受。

     

    Abstract:
      Objective  This study aims to investigate the clinical effects and tolerance of NP chemotherapy combined with intensi ty-modulated radiotherapy in treating stage Ⅲ non-small cell lung cancer (NSCLC)
      Methods  A total of 72 patients with stage Ⅲ NSCLC were divided into two groups, namely, experimental group (EG) and control group (CG). The patients in EG were treated with NP chemotherapy and radiotherapy. The NP regimen included vinorelbine (25 mg/m2, dl, dS) and DDP (75 mg/m2, dl), which was repeated every 21 days. Intensity-modulated radiotherapy was performed on the first day of chemotherapy, with a total dose of 60 Gy to 64 Gy. Meanwhile, patients in CG underwent radiotherapy only.
      Results  The overall response rate among patients who received NP chemotherapy and ra- diotherapy treatment was 72.2% and 41.7% in EG and CG, respectively. The median time to progression (TTP) of the patients in EG and CG was 7.2 and 5.8 months, respectively. Grade 3-4 bone marrow suppression was observed in 20 and five patients in EG and CG, respectively. Grade 3-4 gastrointestinal reaction was observed in six patients in EG and 0 in CG. Radiation esophagitis was observed in four and three patients, whereas radiation pneumonitis was observed in five and two patients in EG and CG, respectively.
      Conclusion  NP chemotherapy combined with intensity-modulated radiotherapy has good therapeutic effects for NSCLC patients, with tolerable toxicity.

     

    • HTML全文
    • 参考文献(16)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回